PhaseWell Research

What PhaseWell Research does

PhaseWell Research is a privately held, multi-site clinical research organization headquartered in Nashville, Tennessee, formed in December 2024 with backing from private equity firm Shore Capital Partners. The company operates a national network of 15 wholly-owned clinical research sites across the US and Puerto Rico, providing Phase I through Phase IV clinical trial services to pharmaceutical sponsors, biotechnology companies, and contract research organizations. PhaseWell's site portfolio spans Renstar Medical Research (CNS, metabolic, dermatology), Gabrail Cancer Center Research (oncology with a dedicated 16-bed Phase 1 unit), Bio Behavioral Health (CNS and psychiatry), Chase Medical Research (multi-therapeutic in Connecticut), Latin Clinical Trial Center (cardiometabolic in Puerto Rico), and the Sargon Research embedded oncology network (6 sites).

The company's core technology is its consolidated site network platform, which provides access to over 15.9 million potential participants across network MSA populations and supports 2300+ completed trials and 195+ drug approvals enabled historically. PhaseWell targets pharmaceutical sponsors (80% of Top 20 served), biotech companies, and CROs (90% of Top 10 served), with go-to-market conducted through enterprise field sales, dedicated business development outreach, and active participation in major industry conferences (DIA, ASH, SCRS, CNS Summit). Revenue is generated through professional services fees for trial execution, patient recruitment and retention, site management, and regulatory compliance across four primary therapeutic areas: oncology, central nervous system, cardiovascular/metabolic, and dermatology. The leadership team, including CEO Carsten Bick (formerly IVX Health), CFO Roberto Ramirez (formerly American Securities), and a board featuring former PPD President David Johnston and Parexel COO Rob Goodwin, brings prior multi-site healthcare scaling experience to support a continued roll-up strategy.

Name

PhaseWell Research

Legal name

SCP Clinical Research Intermediate Holdings, LLC

Website

https://phasewell.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

51–100 employees

Short description

PhaseWell Research is a PE-backed, multi-site clinical research organization operating 15 wholly-owned sites across the US and Puerto Rico, providing Phase I-IV clinical trial services in oncology, CNS, cardiometabolic, and dermatology to pharmaceutical, biotech, and CRO sponsors.

Ownership category

akta.pro rank

Product category

Clinical Research Site Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Post-Approval Clinical Development (Phase IV & Lifecycle Management) (HLAIALAJ)

Keywords

• Clinical trial services
• Multisite clinical research
• Phase I-IV trials
• Clinical research site network
• Therapeutic area research

Headquarters

HQ city

Nashville

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Trial Services: PhaseWell Research generates revenue by providing clinical trial site services to pharmaceutical sponsors, biotech companies, and CROs. The company operates a network of owned and embedded research sites that conduct clinical studies across therapeutic areas including oncology, CNS, cardiovascular/metabolic, and dermatology. Revenue comes from fees for trial execution, patient recruitment and retention services, site management, and regulatory compliance support.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

PhaseWell Research operates a wholly-owned multisite clinical research network that executes Phase I–IV clinical trials for pharmaceutical sponsors, biotechnology companies, and CROs. The network provides site-based services including patient recruitment and retention, regulatory and GCP-compliant trial conduct, data collection, and dedicated Phase 1 capacity across therapeutic areas such as oncology, CNS, cardiometabolic, and dermatology.

Product overview

PhaseWell Research is a unified clinical trial site network platform formed in 2024 through the consolidation of multiple well-established research sites: Renstar Medical Research (CNS, metabolic, dermatology), Gabrail Cancer Center Research (oncology with dedicated Phase I unit), Bio Behavioral Health (CNS/psychiatric), Chase Medical Research (multitherapeutic), and Latin Clinical Trial Center (cardiometabolic, rheumatology, hepatology in Puerto Rico). The network operates 15 site locations across the US, providing Phase I-IV clinical trial services with access to over 15.9 million potential participants. Sargon Research serves as an embedded oncology research sub-network within the platform.

Differentiator

Problem solved

Functional benefit

Products and services

• PhaseWell Clinical Research Site Network A nationally recognized multisite clinical research network providing Phase I–IV clinical trial services across oncology, CNS, cardiovascular/metabolic, and dermatology therapeutic areas for pharmaceutical sponsors, biotech companies, and CROs. The network operates 15 site locations across the U.S. and Puerto Rico with access to over 15.9 million potential participants across its MSA population.
• Renstar Medical Research (acquired site) Community-centric clinical research site network based in Ocala, Florida, operating 4 locations conducting Phase I–IV trials across CNS disorders, metabolic diseases, and dermatology.
• Gabrail Cancer Center Research (acquired site) Oncology-focused clinical research site in Canton, Ohio, operating a dedicated 16-bed Phase 1 unit and conducting oncology trials across early- and late-phase development.
• Bio Behavioral Health (acquired site) CNS and psychiatric clinical research site based in Toms River, New Jersey, conducting Phase I–IV trials across depression, bipolar disorder, ADHD, schizophrenia, Alzheimer's disease, Parkinson's disease, anxiety, and PTSD.
• Chase Medical Research (acquired site) Multitherapeutic clinical research site operating from Hamden and Waterbury, Connecticut, conducting 400+ trials across CNS, metabolic/endocrine, vaccines, women's health, pain management, and general medicine indications.
• Latin Clinical Trial Center (acquired site) Bilingual clinical research site in San Juan, Puerto Rico, conducting 85+ trials across cardiometabolic, rheumatology/immunology, gastroenterology/hepatology, infectious disease, and vaccine research for a predominantly Hispanic patient population.
• Sargon Research (embedded oncology network) Embedded oncology research network with 6 sites across the U.S., powered by Gabrail Cancer Center Research, providing operational infrastructure including contracting, budgeting, regulatory guidance, compliance oversight, patient recruitment, data management, and billing services for community-based oncology trials.

Quantifiable outcome

• 2300+ clinical trials completed across the network
• +3 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core.

• Chase Medical ResearchcoreStrategic or Co-development Partner · 18 March 2026PhaseWell Research acquired Chase Medical Research, which operates clinical trial sites in Waterbury and Hamden, Connecticut. The acquisition expands PhaseWell's Northeast footprint and enhances its cardiometabolic and central nervous system clinical research capabilities. Chase Medical Research brings over 20 years of expertise under founder Dr. Joseph Soufer, supporting PhaseWell's strategy of building a national network of research sites.
• Bio Behavioral Health (BBH)coreStrategic or Co-development Partner · 22 January 2026BBH has entered a partnership with PhaseWell Research to expand access to neuropsychiatric clinical trials, combining BBH's community-based research expertise with PhaseWell's national platform. The collaboration aims to broaden research opportunities for patients while offering sponsors consistent enrollment and operational performance in CNS research. Partnership addresses growing unmet need in neuropsychiatric disorders.
• Latin Clinical Trial Center (LCTC)coreStrategic or Co-development PartnerLatin Clinical Trial Center, a clinical research site located in San Juan, Puerto Rico, has joined PhaseWell Research. Founded in 2006 by Dr. Carlos Sariol, LCTC has 20 years of experience conducting cardiometabolic clinical trials and is known for best-in-class patient engagement and retention. LCTC enhances PhaseWell's national footprint and significantly expands its cardiometabolic capabilities.
• Renstar Medical ResearchcoreStrategic or Co-development PartnerRenstar Medical Research, a clinical trial site network in Florida, has joined PhaseWell Research. Renstar has conducted more than 700 clinical research studies since its founding in 1997, excelling at high-quality, community-centric research across CNS disorders, metabolic diseases, and dermatology.
• Gabrail Cancer Center ResearchcoreStrategic or Co-development PartnerGabrail Cancer Center Research, founded in 1990 and located in Canton, Ohio, has partnered with PhaseWell Research. GCCR has conducted more than 200 Phase I and 500 Phase II-IV oncology studies with a dedicated Phase 1 unit. Also supports Sargon Research, an oncology embedded research network with 6 sites across the US.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medpace: Mid-to-large CRO with strong site relationship network and therapeutic-area specialization in cardiology, oncology, and metabolic. Competes for similar trial placements and embedded site relationships.
• Parexel: Large global CRO with deep investigator site relationships across all trial phases. PhaseWell lists Parexel among its CRO partners and serves as a site network in its trial execution.
• IQVIA: Largest global CRO with extensive site relationships, decentralized trial capabilities, and an in-house site network. Both a customer and a competitor to PhaseWell for sponsor trial placement decisions.
• Syneos Health: Large CRO offering clinical development and site network services across all major therapeutic areas. Competes with PhaseWell for sponsor site placement and operates an embedded site network of similar scale.
• WCG (WIRB-Copernicus Group): Broad incumbent clinical services company spanning IRB, technology, and clinical trial optimization. Overlaps with PhaseWell through site enablement offerings and broader sponsor services portfolio.

Direct peers

• Accel Research Sites: Multi-therapeutic clinical research site network focused on CNS, ophthalmology, vaccines, and general medicine. Compares directly to PhaseWell on size, sponsor relationships, and multi-specialty community site strategy.
• Avania: Clinical research services provider with site management, CRO, and consulting capabilities. Comparable SMO-centric site network model, though with stronger emphasis on medical device and early-phase studies.
• Velocity Clinical Research: PE-backed multi-site clinical research network consolidating community-based research sites across therapeutic areas including CNS, vaccines, and general medicine. Direct analog to PhaseWell's roll-up site model with similar PE sponsor backing.
• Centricity Research: Multi-site clinical research organization formed through PE-backed consolidation of research sites in North America. Closely comparable model as a private-equity-backed SMO/site network competing for similar sponsors and CRO channel partners.
• Civia Health: Multi-site clinical research network with therapeutic focus areas including oncology and chronic disease. Operates with a similar multi-site SMO model and competes for the same pharma/biotech trial placements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/phasewell-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhaseWell Research